Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient

A method of treating, reducing, or alleviating a medical condition in a patient, said method comprising:

• applying a treatment laser to a body portion of a patient using a painting technique, the treatment laser being configured to provide paint brush-type photodynamic therapy (PPDT) using the painting technique to the body portion of the patient by emitting light of a predetermined wavelength that is absorbed by tissue of the body portion of the patient to which a photosensitizer has been applied, the body portion of the patient being afflicted by a medical condition comprising retinal pigment epithelial (RPE) detachment with accumulation of sub-RPE fluid;
• wherein the application of the treatment laser to the body portion of a patient using the painting technique treats the medical condition, reduces the symptoms associated with the medical condition, and/or alleviates the medical condition;
• wherein the PPDT is applied to an eye of the patient to treat the retinal pigment epithelial (RPE) detachment with the accumulation of the sub-RPE fluid;
• and
• wherein the PPDT therapy is applied in combination with the administration of a medication selected from the group consisting of an anti-VEGF, a Rock inhibitor, and/or an acetazolamide to enhance removal of the sub-RPE fluid.

A method of treating, reducing, or alleviating a medical condition in a patient, said method comprising:

• applying a treatment laser to a body portion of a patient using a painting technique, the treatment laser being configured to provide paint brush-type photodynamic therapy (PPDT) using the painting technique to the body portion of the patient by emitting light of a predetermined wavelength that is absorbed by tissue of the body portion of the patient to which a photosensitizer has been applied, the body portion of the patient being afflicted by a medical condition selected from the group consisting of age-related macular degeneration, diabetic retinopathy, peripapillary choroidal neovascularization, idiopathic choroidal neovascularization, neovascularization after a trauma or infection, cancer, an infection of the skin, eyelid, meibomian gland, conjunctiva, cornea, bladder, vagina, cervix, nose, ear, nail, or mouth, an infected mucosa in the body of the patient, and combinations thereof;
• and
• administering cellular inflammatory pathway inhibitors alone or combined with complement inhibitors or macrolides using slow release polymeric nanoparticles in a solution of semifluorinated alkanes to release medication for 1-3 months or more;
• wherein the application of the treatment laser to the body portion of a patient using the painting technique treats the medical condition, reduces the symptoms associated with the medical condition, and/or alleviates the medical condition.